194 related articles for article (PubMed ID: 18308567)
1. Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor.
Winters MP; Crysler C; Subasinghe N; Ryan D; Leong L; Zhao S; Donatelli R; Yurkow E; Mazzulla M; Boczon L; Manthey CL; Molloy C; Raymond H; Murray L; McAlonan L; Tomczuk B
Bioorg Med Chem Lett; 2008 Mar; 18(6):1926-30. PubMed ID: 18308567
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potent and orally bioavailable N,N'-diarylurea antagonists for the CXCR2 chemokine receptor.
Jin Q; Nie H; McCleland BW; Widdowson KL; Palovich MR; Elliott JD; Goodman RM; Burman M; Sarau HM; Ward KW; Nord M; Orr BM; Gorycki PD; Busch-Petersen J
Bioorg Med Chem Lett; 2004 Sep; 14(17):4375-8. PubMed ID: 15357956
[TBL] [Abstract][Full Text] [Related]
3. Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats.
Auten RL; Richardson RM; White JR; Mason SN; Vozzelli MA; Whorton MH
J Pharmacol Exp Ther; 2001 Oct; 299(1):90-5. PubMed ID: 11561067
[TBL] [Abstract][Full Text] [Related]
4. Potent and orally active ET(A) selective antagonists with 5,7-diarylcyclopenteno[1,2-b]pyridine-6-carboxylic acid structures.
Yoshizumi T; Takahashi H; Ohtake N; Jona H; Sato Y; Kishino H; Sakamoto T; Ozaki S; Takahashi H; Shibata Y; Ishii Y; Saito M; Okada M; Hayama T; Nishikibe M
Bioorg Med Chem; 2004 May; 12(9):2139-50. PubMed ID: 15080914
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationships of new disubstituted phenyl-containing 3,4-diamino-3-cyclobutene-1,2-diones as CXCR2 receptor antagonists.
Lai G; Merritt JR; He Z; Feng D; Chao J; Czarniecki MF; Rokosz LL; Stauffer TM; Rindgen D; Taveras AG
Bioorg Med Chem Lett; 2008 Mar; 18(6):1864-8. PubMed ID: 18304809
[TBL] [Abstract][Full Text] [Related]
6. Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists.
Baxter A; Cooper A; Kinchin E; Moakes K; Unitt J; Wallace A
Bioorg Med Chem Lett; 2006 Feb; 16(4):960-3. PubMed ID: 16297626
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists.
Merritt JR; Rokosz LL; Nelson KH; Kaiser B; Wang W; Stauffer TM; Ozgur LE; Schilling A; Li G; Baldwin JJ; Taveras AG; Dwyer MP; Chao J
Bioorg Med Chem Lett; 2006 Aug; 16(15):4107-10. PubMed ID: 16697193
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.
Dwyer MP; Yu Y; Chao J; Aki C; Chao J; Biju P; Girijavallabhan V; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; Rokosz LL; Kaiser B; Li G; Wang W; Stauffer T; Ozgur L; Baldwin J; Taveras AG
J Med Chem; 2006 Dec; 49(26):7603-6. PubMed ID: 17181143
[TBL] [Abstract][Full Text] [Related]
9. Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.
Aki C; Chao J; Ferreira JA; Dwyer MP; Yu Y; Chao J; Merritt RJ; Lai G; Wu M; Hipkin RW; Fan X; Gonsiorek W; Fosseta J; Rindgen D; Fine J; Lundell D; Taveras AG; Biju P
Bioorg Med Chem Lett; 2009 Aug; 19(15):4446-9. PubMed ID: 19525110
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.
Widdowson KL; Elliott JD; Veber DF; Nie H; Rutledge MC; McCleland BW; Xiang JN; Jurewicz AJ; Hertzberg RP; Foley JJ; Griswold DE; Martin L; Lee JM; White JR; Sarau HM
J Med Chem; 2004 Mar; 47(6):1319-21. PubMed ID: 14998320
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and evaluation of novel 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective CXCR2 chemokine receptor antagonists.
Liu S; Liu Y; Wang H; Ding Y; Wu H; Dong J; Wong A; Chen SH; Li G; Chan M; Sawyer N; Gervais FG; Henault M; Kargman S; Bedard LL; Han Y; Friesen R; Lobell RB; Stout DM
Bioorg Med Chem Lett; 2009 Oct; 19(19):5741-5. PubMed ID: 19713110
[TBL] [Abstract][Full Text] [Related]
12. C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.
Chao J; Taveras AG; Chao J; Aki C; Dwyer M; Yu Y; Purakkattle B; Rindgen D; Jakway J; Hipkin W; Fosetta J; Fan X; Lundell D; Fine J; Minnicozzi M; Phillips J; Merritt JR
Bioorg Med Chem Lett; 2007 Jul; 17(13):3778-83. PubMed ID: 17459706
[TBL] [Abstract][Full Text] [Related]
13. Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.
Biju P; Taveras AG; Dwyer MP; Yu Y; Chao J; Hipkin RW; Fan X; Rindgen D; Fine J; Lundell D
Bioorg Med Chem Lett; 2009 Mar; 19(5):1431-3. PubMed ID: 19196511
[TBL] [Abstract][Full Text] [Related]
14. Further optimization of sulfonamide analogs as EP1 receptor antagonists: synthesis and evaluation of bioisosteres for the carboxylic acid group.
Naganawa A; Matsui T; Ima M; Saito T; Murota M; Aratani Y; Kijima H; Yamamoto H; Maruyama T; Ohuchida S; Nakai H; Toda M
Bioorg Med Chem; 2006 Nov; 14(21):7121-37. PubMed ID: 16879970
[TBL] [Abstract][Full Text] [Related]
15. 3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.
Biju P; Taveras A; Yu Y; Zheng J; Chao J; Rindgen D; Jakway J; Hipkin RW; Fossetta J; Fan X; Fine J; Qiu H; Merritt JR; Baldwin JJ
Bioorg Med Chem Lett; 2008 Jan; 18(1):228-31. PubMed ID: 18006311
[TBL] [Abstract][Full Text] [Related]
16. 2,5-Disubstituted pyrrolidine carboxylates as potent, orally active sphingosine-1-phosphate (S1P) receptor agonists.
Colandrea VJ; Legiec IE; Huo P; Yan L; Hale JJ; Mills SG; Bergstrom J; Card D; Chebret G; Hajdu R; Keohane CA; Milligan JA; Rosenbach MJ; Shei GJ; Mandala SM
Bioorg Med Chem Lett; 2006 Jun; 16(11):2905-8. PubMed ID: 16580205
[TBL] [Abstract][Full Text] [Related]
17. 3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists.
Wang Y; Busch-Petersen J; Wang F; Ma L; Fu W; Kerns JK; Jin J; Palovich MR; Shen JK; Burman M; Foley JJ; Schmidt DB; Hunsberger GE; Sarau HM; Widdowson KL
Bioorg Med Chem Lett; 2007 Jul; 17(14):3864-7. PubMed ID: 17524641
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor.
Burch JD; Belley M; Fortin R; Deschênes D; Girard M; Colucci J; Farand J; Therien AG; Mathieu MC; Denis D; Vigneault E; Lévesque JF; Gagné S; Wrona M; Xu D; Clark P; Rowland S; Han Y
Bioorg Med Chem Lett; 2008 Mar; 18(6):2048-54. PubMed ID: 18291643
[TBL] [Abstract][Full Text] [Related]
19. The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor antagonists.
Porter DW; Bradley M; Brown Z; Charlton SJ; Cox B; Hunt P; Janus D; Lewis S; Oakley P; O'Connor D; Reilly J; Smith N; Press NJ
Bioorg Med Chem Lett; 2014 Aug; 24(15):3285-90. PubMed ID: 24974342
[TBL] [Abstract][Full Text] [Related]
20. SAR studies on thiazolo[4,5-d]pyrimidine based CXCR2 antagonists involving a novel tandem displacement reaction.
Hunt F; Austin C; Austin R; Bonnert R; Cage P; Christie J; Christie M; Dixon C; Hill S; Jewell R; Martin I; Robinson D; Willis P
Bioorg Med Chem Lett; 2007 May; 17(10):2731-4. PubMed ID: 17382543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
